Omics! Omics!

Oxford Nanopore is in the process of morphing into a product-focused company, and so must identify specific markets in which they believe na...

Last month at London Calling, Oxford Nanopore announced a consumables and reagent bundle which enables generating six telomere-to-telomere (...

Scale Bioscience o fficially rolled out today - their rep was already talking about it at the Boston Single Cell Symposium I attended yester...

I have multiple drafts of posts trying to finish up my London Calling items and then a long list of ideas in various stages of gestation - a...

London Calling isn't nearly as exhausting as AGBT, but the first day of talks is packed and then follows with the social event that goes...

London Calling was a particularly good opportunity to take stock of Oxford Nanopore's progress to a "fire-and-forget" sample-t...

I'm writing this the eve of Oxford Nanopore's London Calling conference.  This is a big one, as this summer marks the 10th anniversa...

I'm in the airport getting set to jet off to  London Calling  - already spotted a kindred spirit at Logan doing the same, but I could be...

What is now way back in February, Alexander Hoischen presented a talk at AGBT which described early results from an effort to apply PacBio H...

Technologies vying for state-of-the-art in human genome analysis are a recurrent theme in this space, and there are many ideas on this in th...

[Note: after I initially released this, Dr. Abdueva spotted some glitches; I pulled it back for editing & then got swept into London Cal...

An exciting aspect of true single molecule sequencing has been the detection of methylated bases.  Both Oxford Nanopore and Pacific Bioscien...

Readers of this space might have detected a significant slant towards skepticism in my coverage of Illumina Complete Long Reads (iCLR), exac...

A number of academic labs and startups have been trying to build new ways of parallel sequencing of large numbers of peptides using schemes ...

NanoString declaring bankruptcy on the eve of 2024's edition of AGBT was a shock to many at the meeting and then there was confusion: wo...

PacBio announced preliminary earnings yesterday, and the nearly immediate result was a 50% plunge in their share price.  Along with the ea...

A new preprint based on Genomics UK data has identified a set of single base insertion mutations (predominantly a specific A insertion)  in...

It's been just a few weeks since I sat poolside at AGBT with VizGen CEO Terry Lo and Scale Biosciences CEO Giovanna Prout to discuss the...

While I still have a pair of pre-AGBT and AGBT interviews to write up - plus a long list of post ideas inspired by AGBT - breaking news abou...

Some updates on the sequencing instrument vendors, save Ultima Genomics and Element Biosciences which I've covered already.